相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma
Victor A. Levin et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer
K. S. Ramcharan et al.
BRITISH JOURNAL OF CANCER (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Control of the immune response by pro-angiogenic factors
Thibault Voron et al.
FRONTIERS IN ONCOLOGY (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cerebrospinal Fluid Levels of Vascular Endothelial Growth Factor Correlate With Reported Pain and Are Reduced by Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome
Kevin F. McCarthy et al.
NEUROMODULATION (2013)
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T. Batchelor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
Magali Terme et al.
ONCOIMMUNOLOGY (2013)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Vascular Endothelial Growth Factor (VEGF), VEGF Receptors and Their Inhibitors for Antiangiogenic Tumor Therapy
Satoru Takahashi
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2011)
Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Stuart A. Grossman et al.
CLINICAL CANCER RESEARCH (2011)
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme
Camilo E. Fadul et al.
NEURO-ONCOLOGY (2011)
Increase of Plasma VEGF after Intravenous Administration of Bevacizumab Is Predicted by a Pharmacokinetic Model
Marianne O. Stefanini et al.
CANCER RESEARCH (2010)
Targeting STAT3 in Adoptively Transferred T Cells Promotes Their In Vivo Expansion and Antitumor Effects
Maciej Kujawski et al.
CANCER RESEARCH (2010)
A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
Olivier Adotevi et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets
Siegfried Kohler et al.
BLOOD (2009)
Platelets actively sequester angiogenesis regulators
Giannoula Lakka Klement et al.
BLOOD (2009)
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
C. Alfaro et al.
BRITISH JOURNAL OF CANCER (2009)
Arginase I-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes
Paulo C. Rodriguez et al.
CANCER RESEARCH (2009)
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
Christopher G. Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts
Lova Segerstrom et al.
PEDIATRIC RESEARCH (2006)
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients
CG Willett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation
MR Betts et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Complexation of VEGF with bevacizumab decreases VEGF clearance in rats
V Hsei et al.
PHARMACEUTICAL RESEARCH (2002)
Immature myeloid cells and cancer-associated immune suppression
S Kusmartsev et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
分享论文
